LORMETAZEPAM

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H12Cl2N2O2
Molecular Weight	335.185
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3

InChI

InChIKey=FJIKWRGCXUCUIG-UHFFFAOYSA-N

InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3

HIDE SMILES / InChI

Molecular Formula	C16H12Cl2N2O2
Molecular Weight	335.185
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://home.intekom.com/pharm/schering/noctamid.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1687574 https://www.ncbi.nlm.nih.gov/pubmed/6124982

Lormetazepam (or methyl-lorazepam), possesses hypnotic, anxiolytic, sedative and skeletal muscle relaxant properties. Lormetazepam is not approved for sale in the United States or Canada, though it is licensed in the Netherlands as 1 and 2 mg tablets, under the brand names Loramet and Noctamid and as generic, available from several different manufacturers. Lormetazepam is a short-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or falling asleep. Lormetazepam binds to the benzodiazepine receptor which in turn enhances the effect of the GABAA receptor producing its therapeutic effects as well as adverse effects. Lormetazepam appears to be more selective in the type of benzodiazepine receptor it binds to showing a higher affinity for the omega 1 receptor which is responsible for sedation. Changes in electroencephalography can therefore be used to measure the sedative sleep promoting properties of lormetazepam.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; benzodiazepine site 38 Target ID: CHEMBL2109243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1687574	Binding Agent 1064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 108 Sources: http://home.intekom.com/pharm/schering/noctamid.html	Curative		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Simultaneous determination of fifteen low-dosed benzodiazepines in human urine by solid-phase extraction and gas chromatography-mass spectrometry.	2001 Dec 25	11767312
Fast withdrawal from benzodiazepines in geriatric inpatients: a randomised double-blind, placebo-controlled trial.	2002 Jan	11868796
Determination of lormetazepam and its main metabolite in serum using micellar electrokinetic capillary chromatography with direct injection and ultraviolet absorbance detection.	2002 Jun 25	12031841
Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.	2002 Sep	12237787
The use of hypnosedative drugs in a university hospital setting.	2003 Jul-Aug	14635530
Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.	2005 Jan	15763608
Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry.	2005 Oct 15	16154525
Quantification of benzodiazepines in whole blood and serum.	2006 Nov	16220317
Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode.	2007 May	17555647
Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications.	2008	19170404
Use of computerized dynamic posturography to assess balance in older adults after nighttime awakenings using zolpidem as a reference.	2008 Jul 15	18627623
GABA(A) receptors in normal development and seizures: friends or foes?	2008 Mar	19305785
Clinical review: The impact of noise on patients' sleep and the effectiveness of noise reduction strategies in intensive care units.	2009	19344486
Psychoactive medication and traffic safety.	2009 Mar	19440432
Conversion visual loss: a differential diagnosis in infant amblyopia.	2009 Nov-Dec	19882565
Benzodiazepine prescription and length of hospital stay at a Japanese university hospital.	2009 Oct 9	19818119
Analysis of six benzodiazepines in vitreous humor by high-performance liquid chromatography-photodiode-array detection.	2010 Nov	21073805

Patents

Sample Use Guides

In Vivo Use Guide

1 tablet Noctamid (lormetazepam) (1 mg) as a single dose. Elderly and debilitated patients take half a tablet (0,5 mg).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:26:14 GMT 2023` Edited by `admin` on `Fri Dec 15 15:26:14 GMT 2023`
Record UNII	GU56C842ZA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LORMETAZEPAM

Official Name

English

LORMETAZEPAM [USAN]

Common Name

English

7-Chloro-5-(O-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one

Common Name

English

LORMETAZEPAM [MART.]

Common Name

English

2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-3-HYDROXY-1-METHYL-

Systematic Name

English

Lormetazepam [WHO-DD]

Common Name

English

7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-3-HYDROXY-1-METHYL-2H-1,4-BENZODIAZEPIN-2-ONE

Systematic Name

English

LORMETAZEPAM [MI]

Common Name

English

WY-4082

Code

English

LORMETAZEPAM [JAN]

Common Name

English

LORAMET

Brand Name

English

lormetazepam [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1012